StockData
Elicio Therapeutics, Inc. logo

Elicio Therapeutics, Inc. (ELTX) stock

ELTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 1/30
$1.50−0.09 (-5.66%)

Close on Nov 19, 2026Market cap $39.42MP/E –Yield –

Elicio Therapeutics revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Elicio Therapeutics's revenue for the twelve months ending Mar 31, 2023 was $653.00K, down 97.8% year over year. For fiscal 2022 it was $2.30M, down 91.9% from the year before.

Annual revenue

PeriodPeriod endValueChange
FY2022Dec 31, 2022$2.30M-91.9%
FY2021Dec 31, 2021$28.31M+883.1%
FY2020Dec 31, 2020$2.88M–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q1 FY2023Mar 31, 2023$0-100.0%
Q4 FY2022Dec 31, 2022$0-100.0%
Q3 FY2022Sep 30, 2022$0-100.0%
Q2 FY2022Jun 30, 2022$653.00K+20.9%
Q1 FY2022Mar 31, 2022$1.65M+344.2%
Q4 FY2021Dec 31, 2021$25.94M+5551.6%
Q3 FY2021Sep 30, 2021$1.46M+76.5%
Q2 FY2021Jun 30, 2021$540.00K-25.9%
Q1 FY2021Mar 31, 2021$371.00K-57.1%
Q4 FY2020Dec 31, 2020$459.00K–
Q3 FY2020Sep 30, 2020$827.00K–
Q2 FY2020Jun 30, 2020$729.00K–
Q1 FY2020Mar 31, 2020$865.00K–

More Elicio Therapeutics figures

See a number that looks wrong?